SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, announced today that Mohamed Hachicha, Ph.D., has been appointed to the position of Vice President, Research and Development for NexMed USA, effective immediately.
